Access is unequal to weight-loss drugs Ozempic and Wegovy: study
Add Axios as your preferred source to
see more of our stories on Google.
Prescriptions for blockbuster drugs that treat diabetes, obesity and heart disease are soaring, but the mix of payers shows access to the drugs is far from equitable, per a study published in JAMA Health Forum.
Why it matters: Patients on Medicare and Medicaid appear less likely to be able to access the drugs than those with private coverage.
What they found: The USC-led study found a 442% increase in scripts for semaglutide — the active ingredient in diabetes drug Ozempic and anti-obesity and heart disease drug Wegovy — between January 2021 and December 2023.
- There were 2.6 million prescription fills in December 2023 but less than 10% of Ozempic or Wegovy prescriptions went to patients with Medicaid, per the data from IQVIA's National Prescription Audit PayerTrak.
- Less than 30% of Ozempic prescriptions and only 1.2% of Wegovy prescriptions were filled for patients on Medicare Part D plans.
- Roughly 1% or less went to people paying cash.
What they're saying: "If only certain patient populations get access to these medications — those primarily with private insurance, more generous health plans — then there's a huge percentage of the U.S. population that isn't getting access to these medications," said lead author Christopher Scannell.
- "That brings up a very significant equity issue."
Editor's note: This story has been corrected to note the study was led by USC (not UCLA).
